Journals / Türk Yoğun Bakım Dergisi / 2015 / Cilt: 13 - Sayı: 3

Clinical Characteristics of Patients Diagnosed with Synthetic Cannabinoid (Bonsai) Intoxication in Intensive Care Unit

Yoğun Bakım Ünitesinde Takip Edilen Sentetik Kannabinoid (Bonzai) zehirlenmesi Olgularının Klinik Özellikleri

Pages
117–121
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, new types of synthetic cannabinoids are put on the market every day.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In recent years, synthetic cannabinoids (bonsai) poisoning is a widely seen case that needs to be treated in intensive care unit (ICU) in our country.
📊
Key Findings & Data:Material and Method: Patients followed in ICU of Çanakkale Onsekiz Mart University and Çanakkale State Hospital between 2014 and 2015 were studied retrospectively.
💡
Conclusion & Impact:However, new types of synthetic cannabinoids are put on the market every day.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In recent years, synthetic cannabinoids (bonsai) poisoning is a widely seen case that needs to be treated in intensive care unit (ICU) in our country. In this study, it was aimed to discuss the clinical characteristics of patients diagnosed with synthetic cannabinoid intoxication followed in ICU. Material and Method: Patients followed in ICU of Çanakkale Onsekiz Mart University and Çanakkale State Hospital between 2014 and 2015 were studied retrospectively. Results: Twelve cases were included. In neurological system; confusions (n=4), drowsiness (n=7), restlessness/agitations (n=5), hallucinations (n=2), anxieties/ panics (n=3), acute psychosis (n=1) and amnesias (n=11) were detected. One patient was intubated. In cardiovascular system; tachycardias (n=3), bradycardias (n=2), hypertensions (n=2), hypotension (n=1), and arrhythmias (n=2) were observed. In laboratory tests, leukocytosis (n=4), leukopenia (n=1), hypoglycemias (n=3), elevation in liver and renal function tests (n=1) were identified. The average recovery time was 19.3-hours and the average ICU stay was 3-days. Conclusion: In the synthetic cannabinoid intoxication cases; it should be kept in mind that seizure activities may occur in the first hours, myocardial infarction risk in the first 3-days. Liver-kidney functions should be monitored. Hypopotasemia is the most common electrolyte disorder. Cases without any complication are expected to recover in 24-hours. However, new types of synthetic cannabinoids are put on the market every day.

Özet

Amaç: Sentetik kannabinoid (bonzai) zehirlenmesi son yıllarda ülkemizde sık görülen ve yoğun bakım ünitelerinde (YBÜ) takibi gereken bir durumdur. Çalışmamızda YBܒde takip edilen sentetik kannabinoid zehirlenmesi olgularının klinik özelliklerini tartışmayı amaçladık. Gereç ve Yöntem: Çanakkale Onsekiz Mart Üniversitesi ve Çanakkale Devlet Hastanesi YBܒlerinde 2014-2015 yıllarında takip edilen olgular retrospektif olarak tarandı. Bulgular: On iki olgu dahil edildi. Nörolojik sistemde; konfüzyon (n=4), uykuya meyil (n=7), huzursuzluk/ajitasyon (n=5), halusinasyon (n=2), anksiyete/panik (n=3), akut psikoz (n=1), amnezi (n=11) tespit edildi. Bir olgu entübeydi. Kardiyovasküler sistemde; taşikardi (n=3), bradikardi (n=2), hipertansiyon (n=2), hipotansiyon (n=1), aritmi (n=2) gözlendi. Laboratuvar testlerinde, lökositoz (n=4), lökopeni (n=1), hipoglisemi (n=3), karaciğer ve renal fonksiyon testlerinde yükseklik (n=1) tespit edildi. Olguların ortalama bilinç açılma zamanı 19,3 saat, ortalama YBÜ kalış süresi 3 gündü. Sonuç: Sentetik kannabinoid zehirlenmesi olgularında; ilk saatlerde nöbet aktivitesi olabileceği, ilk 3 gün miyokard enfarktüsü riski olduğu akılda tutulmalıdır. Karaciğer ve böbrek fonksiyonlarının takibi gereklidir. Hipopotasemi en sık görülen elektrolit bozukluğudur. Komplikasyonsuz olgular, ilk 24 saat içinde düzelmektedir. Ancak her gün yeni sentetik kannabinoid türlerinin piyasaya sürüldüğü de unutulmamalıdır.

🔖

Cite This Article

ALTINIŞIK, U., ALTINIŞIK, H. B., ŞİMŞEK, T., DOĞU, T., ŞİMŞEK, E., AYDIN, H. (2015). Clinical Characteristics of Patients Diagnosed with Synthetic Cannabinoid (Bonsai) Intoxication in Intensive Care Unit. Türk Yoğun Bakım Dergisi, Cilt: 13 - Sayı: 3, 117–121. https://ajindex.com/articles/327852

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bozkurt M. Sentetik kannabinoidler: Artık herkesin sorunu. Psikiyatride Güncel 2014;4:165-77
  2. Tung C, Chiang T, Lam M. Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry 2012;22:31-3
  3. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 20131;131:106-11
  4. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010;198:31-8
  5. Lewin AH, Seltzman HH, Carroll FI, Mascarella SW, Reddy PA. Emergence and properties of spice and bath salts: A medicinal chemistry perspective. Life Sci 2014;97:9-19
  6. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br J Pharmacol 2010;160:585-93
  7. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005;168:299-325
  8. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012;21:320-6
  9. Brents LK, Gallus-Zawada A, Radominska- Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 2012;83:952-61
  10. Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. Journal of analytical toxicology. J Anal Toxicol 2013;37:534-41
  11. Simmons J, Cookman L, Kang C, Skinner C. Three cases of “spice” exposure. Clin Toxicol (Phila) 2011;49:431-3
  12. Tuv S, Strand M, Karinen R, Oiestad E, Christophersen A, Vindenes V. [Effect and occurrence of synthetic cannabinoids]. Tidsskr Nor Laegeforen 2012;132:2285-8
  13. Schneir AB, Cullen J, Ly BT. “Spice” girls: synthetic cannabinoid intoxication. The J Emerg Med 2011;40:296-9
  14. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int 2009;106:464-7